Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Portola Pharmaceuticals Inc    PTLA

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/16/2018 01/17/2018 01/18/2018 01/19/2018 01/22/2018 Date
50.17(c) 49.75(c) 49.69(c) 49.63(c) 49.59 Last
1 362 891 1 313 313 827 793 648 219 506 347 Volume
-4.66% -0.84% -0.12% -0.12% -0.08% Change
More quotes
Financials ($)
Sales 2017 18,9 M
EBIT 2017 -278 M
Net income 2017 -286 M
Finance 2017 314 M
Yield 2017 -
Sales 2018 203 M
EBIT 2018 -176 M
Net income 2018 -217 M
Finance 2018 133 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 155x
EV / Sales2018 15,3x
Capitalization 3 238 M
More Financials
Company
Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis and other hematologic disorders, and inflammation.Its development-stage portfolio consists of the compounds including Betrixaban, a novel oral once-daily inhibitor of... 
More about the company
Surperformance© ratings of Portola Pharmaceuticals In
Trading Rating : Investor Rating :
More Ratings
Latest news on PORTOLA PHARMACEUTICALS IN
01/19 PORTOLA PHARMACEUTICALS : Researchers Submit Patent Application, "Preparation of..
01/11 PORTOLA PHARMACEUTICALS : Researchers Submit Patent Application, "Preparation of..
2017 PORTOLA PHARMACEUTICALS : Provides Update on Biologics License Application for A..
2017 PORTOLA PHARMACEUTICALS : to Webcast Corporate Update on January 9, 2018
2017 Portola Pharmaceuticals Provides Update on Biologics License Application (BLA..
2017 Portola Pharmaceuticals to Webcast Corporate Update on January 9, 2018
2017 PORTOLA PHARMACEUTICALS : U.S. Food and Drug Administration Approves Prior Appro..
2017 U.S. Food and Drug Administration Approves Prior Approval Supplement for Comm..
2017 PORTOLA PHARMACEUTICALS : Provides Update on European Marketing Authorization Ap..
2017 PORTOLA PHARMACEUTICALS : Analysts See $0.75 EPS for Bank of the Ozarks (OZRK); ..
More news
Sector news : Biotechnology & Medical Research - NEC
06:16p Dealmaking drives European stocks as equity melt-up continues
05:23p Biotech M&A takes off as Sanofi and Celgene spend $20 billion
05:05p CELGENE : to Buy Juno Therapeutics for $9 Billion -- 2nd Update
04:55p Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion
04:48p New drugs recast $10 billion haemophilia market as Sanofi swoops in
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
01/21Portola Pharmaceuticals $PTLA and Immunomedics $IMMU Head-To-Head Comparison .. 
01/21Portola Pharmaceuticals $PTLA Rating Lowered to Strong Sell at BidaskClub  
01/15Want the latest analyst ratings on $PTLA $PGEM $KMDA $WLH $EPZM? Get Them Del.. 
01/11Portola Pharmaceuticals $PTLA Stock Price Up 0%  
01/11Portola Pharmaceuticals $PTLA Receives News Impact Rating of 0.11  
More tweets
Qtime:48
News from SeekingAlpha
01/11 4th-Quarter 2017 Portfolio Review And Price Increase For Integrated BioScI In..
01/03 YOUR DAILY PHARMA SCOOP : Achaogen Is A Compelling Investment, Protalix Gains On..
2017 YOUR DAILY PHARMA SCOOP : Intercept Updates On NASH Trial, GW Pharmaceuticals Pr..
2017 BIOTECH FORUM DAILY DIGEST : Why We Are Passing On Pulse
2017 YOUR DAILY PHARMA SCOOP : Portola BLA Review Process Delayed, DelMar Soars, Alex..
Chart PORTOLA PHARMACEUTICALS IN
Duration : Period :
Portola Pharmaceuticals In Technical Analysis Chart | PTLA | US7370101088 | 4-Traders
Technical analysis trends PORTOLA PHARMACEUTICALS IN
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 73,4 $
Spread / Average Target 48%
EPS Revisions
Managers
NameTitle
William Lis Chief Executive Officer & Director
Hollings Chase Renton Chairman
Mardi C. Dier Chief Financial Officer & Executive Vice President
John T. Curnutte Executive Vice President-Research & Development
John H. Lawrence Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
PORTOLA PHARMACEUTICALS INC1.95%3 238
CELLTRION, INC.--.--%33 774
IQVIA HOLDINGS INC5.21%21 423
LONZA GROUP2.62%20 876
INCYTE CORPORATION-1.64%19 660
ALNYLAM PHARMACEUTICALS, INC.-1.75%12 275